The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
This article presents a general discussion on what has been achieved so far and on the possible future developments of targeted alpha (α)-particle therapy (TAT). Clinical applications and potential benefits of TAT are addressed as well as the drawbacks, such as the limited availability of relevant radionuclides. Alpha-particles have a particular advantage in targeted therapy because of their high potency and specificity. These features are due to their densely ionizing track structure and short path length. The most important consequence, and the major difference compared with the more widely used β(-)-particle emitters, is that single targeted cancer cells can be killed by self-irradiation with α-particles. Several clinical trials on TAT have been reported, completed, or are on-going: four using (213)Bi, two with (211)At, two with (225)Ac, and one with (212)Pb/(212)Bi. Important and conceptual proof-of-principle of the therapeutic advantages of α-particle therapy has come from clinical studies with (223)Ra-dichloride therapy, showing clear benefits in castration-resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 3×
“injected 223Ra-dicloride (Xofigo®, formerly named Alpharadin) in a placebo-controlled phase III trial for castration-resistant prostate cancer metastases (20).”
BackgroundInfluentialRubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Bolch, W. E., Eckerman, K. F., Sgouros, G., & Thomas, S. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056036 · Cited by 913 · cited 1×
“The basic concepts of dosimetry are presented in two Medical Internal Radiation Dose (MIRD) publications (46, 47).”
BackgroundIonizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis.
Haimovitz-Friedman, A., Kan, C. C., Ehleiter, D., Persaud, R. S., McLoughlin, M., Fuks, Z., & Kolesnick, R. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.525 · Cited by 905
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · cited 4×
“, α-particle irradiation is 3–7 times more therapeutically effective, or toxic, per unit of absorbed dose than photons or electrons (47).”
BackgroundInfluentialTargeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., & Bigner, D. D. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046938 · Cited by 410
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Bruland, Ø. S., Nilsson, S., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 357 · cited 1×
“In TAT clinical studies, an RBE of five has been applied to estimate the equivalent absorbed doses (10, 14, 48).”
MethodMIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M., Green, A. J., Zanzonico, P. B., Frey, E. C., SNMMI MIRD Committee, Bolch, W. E., Brill, A. B., Dunphy, M., Fisher, D. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 336
Radiation-induced cell signaling: inside-out and outside-in
Valerie, K., Yacoub, A., Hagan, M. P., Curiel, D. T., Fisher, P. B., Grant, S., & Dent, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0596 · Cited by 324
Andersson, H., Cederkrantz, E., Bäck, T., Divgi, C., Elgqvist, J., Himmelman, J., Horvath, G., Jacobsson, L., Jensen, H., Lindegren, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.062604 · Cited by 298 · cited 8×
“route of administration was used in nine patients with recurrent ovarian carcinoma using 211At-MX35, an antibody against sodium-dependent phosphate transport protein 2b (NaPi2b) (10).”
BackgroundMethodSelf-citationRosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 271 · cited 1×
“It is suggested that when introducing TAT directly after chemotherapy, the cytoreductive effect of the chemotherapy can enhance the possibility of a saturation of CD33 sites by the targeted drug, which will increase the number of radionuclides delivered to leukemia cells without the need for activity escalation (13).”
BackgroundBarendsen, G. W., Beusker, T. L. J., Vergroesen, A. J., & Budke, L. (1960) · Radiation Research · doi:10.2307/3570859 · Cited by 255
Clinical radioimmunotherapy—the role of radiobiology
Pouget, J.-P., Navarro-Teulon, I., Bardiès, M., Chouin, N., Cartron, G., Pèlegrin, A., & Azria, D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.160 · Cited by 250 · cited 1×
“While conventional EBRT is characterized by high absorbed doses delivered in a very short time in a homogenous way, TAT and radionuclide therapy in general are characterized by a low absorbed dose rate, protracted exposure, and heterogeneous energy deposit (63).”
BackgroundSelf-citationDelayed repair of radiation induced clustered DNA damage: Friend or foe?
Eccles, L. J., O’Neill, P., & Lomax, M. E. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2010.11.003 · Cited by 234 · cited 1×
“These lesions, produced in close proximity to each other, are poorly repairable, thus making α-particles highly deleterious (61, 62).”
BackgroundPretargeted radioimmunotherapy of cancer: progress step by step.
Boerman, O. C., van Schaijk, F. G., Oyen, W. J. G., et al. (2003) · PubMed · Cited by 216
Barendsen, G. W., Walter, H. M. D., Fowler, J. F., & Bewley, D. K. (1963) · Radiation Research · doi:10.2307/3571430 · Cited by 211
Sgouros, G., Ballangrud, Å., Jurcic, J. G., McDevitt, M. R., Humm, J. L., Erdi, Y. E., Mehta, B. M., Finn, R. D., Larson, S. M., & Scheinberg, D. A. (1999) · PubMed · Cited by 207
Cordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Müller-Brand, J., Mäcke, H., Reubi, J. C., & Merlo, A. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1385-5 · Cited by 204 · cited 2×
“Eur J Nucl Med Mol Imaging (2010) 37(7):1335–44.”
BackgroundAstatine-211: Production and Availability
R. Zalutsky, M., & Pruszynski, M. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104030177 · Cited by 200 · cited 2×
“A major issue that may hamper wide implementation in the clinic and that needs to be simultaneously addressed is the availability of suitable α-particle emitters at a reasonable cost (43, 89).”
BackgroundAvidin-biotin technology in targeted therapy
Lesch, H. P., Kaikkonen, M. U., Pikkarainen, J. T., & Ylä-Herttuala, S. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425241003677749 · Cited by 200 · cited 1×
“Efficient interaction between the pre-targeting molecule and the effector molecule has been achieved using a handful of techniques, particularly those based on streptavidin-biotin (81) or bispecific antibodies (82).”
Gulston, M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh306 · Cited by 196 · cited 1×
“These lesions, produced in close proximity to each other, are poorly repairable, thus making α-particles highly deleterious (61, 62).”
BackgroundVerheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., Markowska, J., Vyzula, R., Jobling, T., Stamp, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5973 · Cited by 193 · cited 1×
“Therefore, local treatment with the β-particle-emitting radioconjugate 90Y-HFMG (human milk fat globule-1, a mAb toward MUC-1) was investigated in a large randomized controlled phase III trial, but overall survival did not improve, although a slight decrease in local intraperitoneal recurrence was observed (39, 40).”
BackgroundApostolidis, C., Molinet, R., McGinley, J., Abbas, K., Möllenbeck, J., & Morgenstern, A. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.06.013 · Cited by 176 · cited 1×
“The possibility of producing 225Ac by use of a cyclotron via the 226Ra (p, 2n) 225Ac is now also investigated (42).”
BackgroundMeredith, R. F., Torgue, J. J.-C., Azure, M. T., Shen, S., Saddekni, S., Banaga, E., Carlise, R., Bunch, P., Yoder, D., & Alvarez, R. D. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1531 · Cited by 168
Radiobiology of α Particles: III. Cell Inactivation by α-Particle Traversals of the Cell Nucleus
Raju, M. R., Eisen, Y., Carpenter, S., & Inkret, W. C. (1991) · Radiation Research · doi:10.2307/3578139 · Cited by 167
Radiobiological aspects of low dose rates in radioimmunotherapy
Fowler, J. F. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90467-x · Cited by 165
Kneifel, S., Cordier, D., Good, S., Ionescu, M. C. S., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2820 · Cited by 154
Pouget, J., Santoro, L., Raymond, L., Chouin, N., Bardiès, M., Mollévi, C., Huguet, H., Azria, D., Kotzki, P., Pèlegrin, M., et al. (2008) · Radiation Research · doi:10.1667/rr1359.1 · Cited by 144
Self-citationMolecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang, C., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J., Barbet, J., & Goldenberg, D. M. (2002) · PubMed · Cited by 129
Intralesional targeted alpha therapy for metastatic melanoma
Allen, B. J., Raja, C., Rizvi, S., Li, Y., Tsui, W., Graham, P., Thompson, J., Reisfeld, R., Kearsley, J., Morgenstern, A., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.12.2251 · Cited by 124 · cited 2×
“cancers (11), myelogenous leukemia (12–16), nonHodgkin lymphoma (17), and metastatic melanoma (18, 19).”
BackgroundGlimelius, B. L. G., Dahl, O., Cedermark, B., Jakobsen, A. K. M., Bentzen, S. M., Starkhammar, H., Grönberg, H., Hultborn, R., Albertsson, M., Påhlman, L., et al. (2005) · Acta Oncologica · doi:10.1080/02841860500355900 · Cited by 115
Barendsen, G. W. (1964) · International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine · doi:10.1080/09553006414550561 · Cited by 113
Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
Pool, S. E., Krenning, E. P., Koning, G. A., van Eijck, C. H. J., Teunissen, J. J. M., Kam, B. L. R., Valkema, R., Kwekkeboom, D. J., & de Jong, M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.001 · Cited by 110 · cited 6×
“Nucleic Acids Res (2004) 32(4):1602–9.”
BackgroundInfluentialZhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D. B., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., & Waldmann, T. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437788100 · Cited by 108 · cited 1×
“Several preclinical studies have shown the benefits of pretargeted α therapy (PTAT), mainly in hematological cancers, such as AML (83), non-Hodgkin lymphoma (84), anaplastic large cell lymphoma (85), and adult T-cell leukemia (85).”
BackgroundBarendsen, G. W., & Walter, H. M. D. (1964) · Radiation Research · doi:10.2307/3571569 · Cited by 107
Options to meet the future global demand of radionuclides for radionuclide therapy
Das, T., & Pillai, M. R. A. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.09.007 · Cited by 104 · cited 1×
“A major issue that may hamper wide implementation in the clinic and that needs to be simultaneously addressed is the availability of suitable α-particle emitters at a reasonable cost (43, 89).”
BackgroundAllen, B. J., Singla, A. A., Rizvi, S. M. A., Graham, P., Bruchertseifer, F., Apostolidis, C., & Morgenstern, A. (2011) · Immunotherapy · doi:10.2217/imt.11.97 · Cited by 93 · cited 3×
“cancers (11), myelogenous leukemia (12–16), nonHodgkin lymphoma (17), and metastatic melanoma (18, 19).”
BackgroundWard, B. G., Mather, S. J., Hawkins, L. R., Crowther, M. E., Shepherd, J. H., Granowska, M., Britton, K. E., & Slevin, M. L. (1987) · PubMed · Cited by 87
Lethal Mutations and Cell Death
Alper, T. (1963) · Physics in Medicine and Biology · doi:10.1088/0031-9155/8/4/301 · Cited by 85
Prospects in Folate Receptor-Targeted Radionuclide Therapy
Müller, C., & Schibli, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00249 · Cited by 78 · cited 5×
“Int J Radiat Oncol Biol Phys (2004) 59(5):1274–87.”
BackgroundInfluentialGleisner, K. S., Ljungberg, M. H., & Strand, S. (2002) · PubMed · Cited by 75
Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
Hernandez, M. C., & Knox, S. J. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.02.065 · Cited by 74
Barendsen, G. W., & Beusker, T. L. J. (1960) · Radiation Research · doi:10.2307/3570858 · Cited by 73
Park, S. I., Shenoi, J., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Orgun, N., Kenoyer, A. L., Frayo, S., Axtman, A., Bäck, T., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282327 · Cited by 73 · cited 1×
“Several preclinical studies have shown the benefits of pretargeted α therapy (PTAT), mainly in hematological cancers, such as AML (83), non-Hodgkin lymphoma (84), anaplastic large cell lymphoma (85), and adult T-cell leukemia (85).”
BackgroundA Formalism for Calculation of Absorbed Dose from Radionuclides
LOEVINGER, R., & Berman, M. (1968) · Physics in Medicine and Biology · doi:10.1088/0031-9155/13/2/306 · Cited by 70 · cited 1×
“DOSIMETRY Dosimetry was originally developed for radiation protection (44) and diagnostic imaging (45), but is now also needed for optimization of the therapeutic situation using radiopharmaceuticals.”
BackgroundRadiotherapy Effects on Anti-Tumor Immunity: Implications for Cancer Treatment
Demaria, S., & Formenti, S. C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00128 · Cited by 69
The in Vitro Radiobiology of Astatine-211 Decay
Kassis, A. I., Harris, C. R., & Adelstein, S. J. (1986) · Radiation Research · doi:10.2307/3576722 · Cited by 66
Andersson, H., Elgqvist, J., Horváth, G., Hultborn, R., Jacobsson, L., Jensen, H. J., Karlsson, B., Lindegren, S., & Palm, S. (2003) · PubMed · Cited by 64
Self-citationPagel, J. M., Kenoyer, A. L., Bäck, T. A., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Park, S. I., Frayo, S. L., Axtman, A., Orgun, N. N., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347039 · Cited by 63 · cited 2×
“Additionally, an on-going investigation is using the combination of 225Ac-lintuzumab and the cytotoxic drug cytarabine in older patients with acute myeloid leukemia (AML) (16).”
BackgroundRadiocolloids in the Treatment of Ovarian Cancer
ROSENSHEIN, N. B., LEICHNER, P. K., & VOGELSANG, G. (1979) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-197909000-00028 · Cited by 62 · cited 1×
“radiotherapy with colloid preparations of 198Au or 32P as adjuvant therapies (33, 34).”
Olafsen, T., Kenanova, V. E., & Wu, A. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.322 · Cited by 56 · cited 1×
“Clearance and tumor uptake vary with size and pharmacokinetic properties, and mAb can now even be tailor-made (6).”
BackgroundJain, M. R., Li, M., Chen, W., Liu, T., de Toledo, S. M., Pandey, B. N., Hong Li, A., Rabin, B. M., & Azzam, E. I. (2011) · Current Molecular Pharmacology · doi:10.2174/1874-470211104020106 · Cited by 52
Advances in Anticancer Radiopharmaceuticals
Jackson, M. R., Falzone, N., & Vallis, K. A. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.06.004 · Cited by 50 · cited 1×
“Radionuclides that emit Auger electrons could offer an alternative approach compared with the nuclides described in this article, reviewed elsewhere (88).”
MethodProduction of 230U/226Th for Targeted Alpha Therapy via Proton Irradiation of 231Pa
Morgenstern, A., Lebeda, O., Štursa, J., Bruchertseifer, F., Capote, R., McGinley, J., Rasmussen, G., Sin, M., Zielinska, B., & Apostolidis, C. (2008) · Analytical Chemistry · doi:10.1021/ac801304c · Cited by 49 · cited 1×
“Studies on the feasibility of producing (230)U and its daughter (226)Th via proton irradiation of (231)Pa according to the (231)Pa (p, 2n) (230)U reaction have been performed (29).”
Senekowitsch–Schmidtke, R., Schuhmacher, C. P., Becker, K., Nikula, T. K., Seidl, C., Becker, I., Miederer, M., Apostolidis, C., Adam, C., Huber, R., et al. (2001) · PubMed · Cited by 42
Walicka, M. A., Vaidyanathan, G., Zalutsky, M. R., Adelstein, S. J., & Kassis, A. I. (1998) · Radiation Research · doi:10.2307/3579974 · Cited by 39
Elgqvist, J., Andersson, H., Bäck, T. A., Claesson, I., Hultborn, R., Jensen, H. J., Lindegren, S., Olsson, M., Palm, S., Warnhammar, E., et al. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.07.009 · Cited by 39 · cited 1×
“Fractionated RIT is another potentially interesting regimen to improve the therapeutic index, thus resulting in reduced normal organ toxicity while maintaining the therapeutic efficacy (87).”
BackgroundSelf-citationRadioimmunotherapy of B-cell non-Hodgkin’s lymphoma
Bodet‐Milin, C., Ferrer, L., Pallardy, A., Eugène, T., Rauscher, A., Faivre-Chauvet, A., Barbet, J., & Kraeber-Bodéré, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00177 · Cited by 39 · cited 1×
“RIT with the longer range, low energyβ-particle-emitting conjugates (Zevalin®/Bexxar®) is useful for the more bulky lymphomas and are approved for follicular B-cell non-Hodgkin lymphoma, but comes with long-lasting bone marrow toxicity (28).”
BackgroundMicrodosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusion
Palm, S., Humm, J. L., Rundqvist, R., & Jacobsson, L. (2004) · Medical Physics · doi:10.1118/1.1640951 · Cited by 38
Yang, G., Wu, L., Chen, S., Zhu, L., Huang, P., Tong, L., Zhao, Y., Zhao, G., Wang, J., Mei, T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605087 · Cited by 36
Lorimore, S. A., Rastogi, S., Mukherjee, D., Coates, P. J., & Wright, E. G. (2013) · Radiation Research · doi:10.1667/rr3158.2 · Cited by 31
Vaidyanathan, G., Boskovitz, A., Shankar, S., & Zalutsky, M. R. (2004) · Peptides · doi:10.1016/j.peptides.2004.08.018 · Cited by 30 · cited 1×
“, optimized treatment of neuroendocrine tumors expressing somatostatin receptors, using the synthetic ligand octreotate (23), which today are treated with β-particles such as 177Lu, if kidney toxicity could be shown to be less.”
BackgroundPatient-Specific Alpha-Particle Dosimetry
Palm, S., Elgqvist, J., & Jacobsson, L. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104040329 · Cited by 7 · cited 2×
“α-Particle dosimetry in the clinic require pharmacokinetic data similar to those that are required for conventional β–-particle therapies (22), e.”
BackgroundMethodSelf-citation
Cited by
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
“Importantly, α-particle lethality is not dependent on the cell cycle or oxygenation, and the DNA damage is often via double strand and DNA cluster breaks and is therefore much more difficult to repair than β− damage [6].”
BackgroundInfluentialDevelopment of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Metadata
- Authors
- Elgqvist, J., Frost, S., Pouget, J.-P., & Albertsson, P.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 3
- Pages
- 324-324
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2000403342
- Cited by
- 194
- References
- 68
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.